Unlock instant, AI-driven research and patent intelligence for your innovation.

Drug and food/drink for preventing or improving cerebral dysfunction

Inactive Publication Date: 2013-08-01
HASEGAWA HIROYUKI
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a new substance called sepiapterin that can improve symptoms of various types of brain dysfunction. The substance is able to pass through the blood-brain barrier, which is a barrier that restricts the movement of substances from the blood to the brain. The substance is discharged from the brain either by active outward transport or by returning to the blood stream without being taken up into the brain. This patent is important because it explains how sepiapterin can potentially benefit brain health.

Problems solved by technology

However, it has been pointed out that since an SSRI decreases the total amount of serotonin in neurons, the drug may further exacerbate symptoms of depression for longer administration.
However, as in the case of an SSRI, it has been pointed out that an SNRI also decreases the total amount of serotonin in neurons and may exacerbate symptoms of depression on longer administration.
That is, tetrahydrobiopterin is extremely difficult in passing through the blood-brain barrier.
However, this substance amounts in trace and is nearly undetectable in blood or urine.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug and food/drink for preventing or improving cerebral dysfunction
  • Drug and food/drink for preventing or improving cerebral dysfunction
  • Drug and food/drink for preventing or improving cerebral dysfunction

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0102]In Example 1, where PC12 cells and RBL2H3 cells were used as aromatic monoamine synthesizing cells and sepiapterin was added to a culture medium, evaluation was made for a total amount of biopterin in the cells (a total amount of tetrahydrobiopterin, and its oxidant, dihydrobiopterin and biopterin, the same shall apply hereinafter).

[0103]The PC12 cells are cultured cells having properties of a neuron and it is known that they synthesize dopamine, noradrenaline and adrenaline, with tetrahydrobiopterin used as a coenzyme. The RBL2H3 cells are cultured cells having properties of a mast cell and it is known that they synthesize serotonin, with tetrahydrobiopterin used as a coenzyme.

[0104]The both cells are capable of synthesizing tetrahydrobiopterin and also retain a certain amount of tetrahydrobiopterin in the cells but do not retain a saturated amount thereof. Furthermore, unlike cells which are not capable of synthesizing aromatic monoamines by themselves but take up aromatic m...

example 2

[0119]In Example 2, a cell system of a brain blood vessel wall model was used to compare passage of sepiapterin with that of tetrahydrobiopterin across a blood vessel wall.

[0120]As the brain blood vessel wall model, there was used a “BBB kit, RBT24H (made by PharmaCo-Cell Company Ltd. in Japan).” This kit was a model system in which rat vascular endothelical cells were cultured on a porous synthetic resin film having small pores of 3 μm in inner diameter to form tight intercellular junctions, thereby forming the blood vessel wall. In this kit, pericytes were cultured in advance on the back side of the porous synthetic resin film and astroglia cells were also cultured at the same time in the well below the film, thereby forming the intercellular tight junctions of vascular endothelical cells. A cultured area was 0.3 cm2 per well. In this model, the cell sheet, an upper side of the cell sheet and a lower side of the cell sheet respectively correspond to the blood vessel wall, an intra...

example 3

[0128]In Example 3, comparison was made between sepiapterin and tetrahydrobiopterin in terms of uptake into astroglia cells.

[0129]The astroglia cells are major glia cells and present tightly around vessels of the brain. This cell selectively takes up a substance which has passed through the blood vessel walls of the brain and supplies the substance to neurons.

[0130]Therefore, CTX TNA2 cells, that is, cultured cells derived from the astroglia cells, were used to evaluate the uptake of sepiapterin and that of tetrahydrobiopterin into the astroglia cells. It is noted that the CTX TNA2 cells used were obtained from the ATCC in the U.S.A. (American Type Culture Collection).

[0131]On a previous day of the experiment, the CTX TNA2 cells were inoculated at 1×105 per well. Thirty minutes after a culture medium was replaced by Hank's-HEPES (pH 7.4), sepiapterin was added at 50 μM or tetrahydrobiopterin was added at 100 μM, each of which was cultured for 0, 5, 10, 20, 40 and 60 minutes. After c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Dimensionless propertyaaaaaaaaaa
Concentrationaaaaaaaaaa
Body weightaaaaaaaaaa
Login to View More

Abstract

[Problem]To provide means for improving symptoms of cerebral dysfunction.[Solution Means]The inventor has newly found that peripheral administration of sepiapterin increases the bioavailability of aromatic monoamines in the brain. Accordingly, provided are a drug for preventing or improving cerebral dysfunction, which contains at least one of sepiapterin and its salt and also provided is a food and or drink for preventing or improving cerebral dysfunction, which contains at least one of sepiapterin and its salt. Unlike tetrahydrobiopterin, etc., sepiapterin is able to repress the lowering level of aromatic monoamines (such as serotonin, dopamine and noradrenaline) in neurons in the brain and also increase the bioavailability. Therefore, sepiapterin may be effective against cerebral dysfunction caused by the lowered level of aromatic monoamines in the brain in neurons in the brain, for example, central mental disorders such as depression, hyperphagia, autism, impaired consciousness and concentration, and cognitive disturbance as well as central motor disorders such as myotonia, rigidity and tremor.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a drug and food / drink which contain sepiapterin for preventing or improving cerebral dysfunction. More specifically, the present invention relates to a drug and food / drink for preventing, improving and treating diseases in which neurotransmitters in the brain are involved, for example, central mental disorders (such as depression, hyperphagia, autism, impaired consciousness and concentration, and cognitive disturbance) or central motor disorders (such as myotonia, rigidity and tremor).BACKGROUND ART[0002]The brain is the highest center of information transmission via nerves such as motor and consciousness, playing an important role in human mental activities such as feeling, emotion and reason as well as optional control of motor. The brain is constructed with an innumerable number of neurons, and information between the neurons is transmitted by neurotransmitters in the brain.[0003]A monoamine neurotransmitter is a generi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/519A23L1/29A23L33/00
CPCA23L1/30A23L2/52A23L1/296C07D475/04A61K31/519A23L33/10A61P25/00A61P25/14A61P25/16A61P25/24A61P25/28A61P43/00
Inventor HASEGAWA, HIROYUKIAIZAWA, SHIN
Owner HASEGAWA HIROYUKI